Dr. He has been engaged in the pharmaceutical industry for more than 30 years. In 2018, he established CureGene and served as CEO. Prior to this, Dr. He worked as a Scientist and senior R&D Director in the U.S. headquarter of Gilead Science Inc. Later he was expatriated to China and served as the chief representative officer and GM of Gilead Science in China.
Dr. He has participated in and led the research and development of several international best-in-class new drugs, and he is the key inventor and project leader of TAF, a widely used anti-HIV/HBV drug in the world. Dr. He is also a co-inventor of several antiviral therapies. Dr. He has rich R&D experience and extensive achievements in the fields of cardiovascular, cerebrovascular, nucleic acid and various antiviral therapies.
Dr. He has extensive experience and profound industry insights in the field of chemical synthesis, R&D project management, supply chain management and corporate management. During his tenure as the chief representative officer and GM of Gilead China, he has gained comprehensive understanding of the pharmaceutical operation system in China and accumulated extensive resources.
Dr. He holds a Ph.D. in synthetic chemistry from Kyushu University, Japan, and completed postdoctoral research at the University of California, Santa Barbara, U.S.
